Fractyl Health, INC 10-Q quarterly reports

Fractyl Health's Q2 2026 report highlights clinical advancements in metabolic disease treatments but raises substantial doubt about its ability to continue as a going concern.

Fractyl Health reports a significant swing to net income in Q1 2026, driven by favorable changes in warrant liabilities, despite a decrease in research and development expenses.

Fractyl Health, Inc. reported a significant increase in net loss for Q3 2025, alongside positive 3-month data from its Revita REMAIN-1 Midpoint Cohort and progress in its Rejuva gene therapy platform.

Fractyl Health, Inc. reported significant net losses and a going concern warning, despite progress in clinical trials and a recent capital raise deemed insufficient for long-term operations.

Fractyl Health is focusing on its REMAIN-1 pivotal study and advancing its Rejuva gene therapy platform after a strategic reprioritization.

Fractyl Health's Q3 2024 report details financial results and progress in clinical trials for their metabolic disease therapies.

Fractyl Health's second quarter 2024 results show increased operating expenses due to clinical trial advancements and public company costs, alongside a net loss of $20.6 million.

Fractyl Health's first quarter 2024 results show a net loss of $3.3 million, but also reflect the impact of a successful IPO and increased cash reserves.